Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients

Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

KLRS

0.00
Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.